A Day Up For X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. (XFOR:NASDAQ) shot up at $1.25, a gain of 40.2%. On Tue, Sep 27, 2022, XFOR:NASDAQ hit a New 2-Week High of $1.25. The stock got featured on our News Catalysts scanner on Tue, Sep 27, 2022 at 08:53 AM in the 'BIOTECH' category. From Tue, Sep 13, 2022, the stock recorded 20.00% Up Days and 27.27% Green Days
About X4 Pharmaceuticals, Inc. (XFOR:NASDAQ)
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.
Top 10 Gainers:
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 106.25%
- Scienjoy Holding Corporation (SJ:NASDAQ), 47.9%
- Sonendo Inc. (SONX:NYSE), 42.74%
- X4 Pharmaceuticals, Inc. (XFOR:NASDAQ), 40.18%
- Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 37.46%
- Grove Collaborative Holdings Inc. Class A (GROV:NYSE), 35.47%
- InMed Pharmaceuticals Inc. (INM:NASDAQ), 31.31%
- AN2 Therapeutics Inc. (ANTX:NASDAQ), 31.13%
- Intelligent Living Application Group Inc. (ILAG:NASDAQ), 28.43%
- Harrow Health, Inc. (HROW:NASDAQ), 27.86%